Skip to content

Multiomics study of the pathogenesis and progression of diffuse large B-cell lymphoma

Multiomics study of the pathogenesis and progression of diffuse large B-cell lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075412
Enrollment
Unknown
Registered
2023-09-04
Start date
2023-10-01
Completion date
Unknown
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B cell lymphoma

Interventions

Sponsors

The Second Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria (except health group) : 1) Diffuse large B-cell lymphoma (experimental group) or lymph node reactive hyperplasia (lymph node reactive hyperplasia group) was pathologically confirmed; 2) Patients =18 years old; 3) Detailed clinical data such as age, sex, the first four items of blood transfusion and lactate dehydrogenase were registered in all enrolled cases; 4) Sign informed consent, fully understand and comply with the requirements of the research scheme, and have the intention to complete the study as planned. Inclusion criteria (health group) : 1) =18 years old; 2) Those who deny serious diseases, infectious diseases, chronic diseases and hereditary diseases, such as tumors, diabetes, hypertension, etc.; 3) Physical examination items include blood routine, liver and kidney function, abdominal color ultrasound, chest radiograph, and the results are normal; 4) The enrolled cases were all registered with detailed basic information, such as age, sex, etc. 5) Sign informed consent, fully understand and comply with the requirements of the research scheme, and have the intention to complete the study as planned.

Exclusion criteria

Exclusion criteria: 1) A history of other malignancies; 2) Severe cardiovascular and cerebrovascular diseases, coagulation, autoimmune and infectious diseases, etc.; 3) Pregnant and lactating women; 4) Any other condition in which the investigator considers the patient not eligible to participate in the study.

Design outcomes

Primary

MeasureTime frame
RNA;DNA;protein;metabolin;

Countries

China

Contacts

Public ContactZeping Zhou

The Second Affiliated Hospital of Kunming Medical University

zhouzeping@outlook.com+86 187 8857 1605

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026